Cinven buys Mercury Pharma from HgCapital for $732 mln

LONDON Fri Aug 17, 2012 12:47pm IST

Related Topics

Stocks

   

LONDON Aug 17 (Reuters) - Investor HgCapital has sold British pharmaceutical company Mercury Pharma to private equity firm Cinven for 465 million pounds ($732 million).

"The realisation of Mercury Pharma marks the continued development of HgCapital's investment focus in the healthcare sector," said HgCapital's head of healthcare, Philipp Schwalber, in a statement on Friday.

"We continue to seek out businesses that enjoy niches of secular growth despite the challenges facing much of the healthcare space," he said.

HgCapital bought the 25-year-old pharmaceutical firm, which sells niche prescription off-patent products in the UK, Ireland and the Netherlands, in 2009.

It said its listed investment trust HgCapital Trust expects to receive 35.4 million pounds in cash on the sale completion and further potential proceeds of 1 million pounds over the next 30 months.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Markets

REUTERS SHOWCASE

Segway in India

Segway in India

Segway’s India business pegs hope on tech-savvy Modi  Full Article 

Power Outage

Power Outage

Mumbai hit by power cuts  Full Article 

Commodities

Commodities

Gold imports, premiums to jump on festive demand - top refiner  Full Article 

Economic Worries

Economic Worries

Pakistan's promises to IMF in doubt as protests sap economy   Full Article 

Islamic Finance

Islamic Finance

Basel III deposit challenge looms over Islamic banks   Full Article 

Antitrust Probes

Antitrust Probes

U.S. business lobby says concerned China antitrust probes unfair.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage